News

Nathan Steinle, MD, spoke with Modern Retina's editor to give insights into his Retina Society presentation titled, "Phase 3 studies of dual inhibition of VEGF C/D and VEGF A using OPT-302 in combination With ranibizumab (ShORe Trial) or aflibercept (COAST Trial) in neovascular AMD."

At the 56th annual Retina Society congress in New York, David Boyer, MD, gave a presentation titled, "Subgroup analyses of phase 1 DAVIO Trial of EYP-1901 demonstrating reduced treatment burden in wet age-related macular degeneration."

Sophie Bakri, MD, MBA, shared insights from her presentation, "Comparison of the Antiangiogenic Profile of Tyrosine Kinase Inhibitors Vorolanib, Axitinib, and Sunitinib."

Researchers note their work reports a novel candidate gene for FEVR, which expands the spectrum of EMC1 variants and EMC1-related phenotypes, providing evidence for the prenatal diagnosis of candidate disease-causing EMC1 variants in FEVR.

The patent covers the company’s development of this cell transplant therapy as a treatment for geographic atrophy.

The use of silicone-free syringes advised with these drops.

The Phase 3 DIAMOND trial of OCS-01 in Diabetic Macular Edema (DME) presents encouraging results, meeting primary and secondary endpoints.

The investigators performed clinical examinations and obtained fundus photographs and inferior optical coherence tomography (OCT) images for both treatments at baseline and on days 1, 3, 8, 15, and 56 after the injections.

A modified endolaser setup was found to be safe and efficient for use during chandelier scleral buckling.

Michael Engelbert, MD, PhD, discusses how personalized faricimab dosing shows promise in extending dosing intervals for patients with wet age-related macular degeneration, which can enhance long-term treatment outcomes and patient adherence.

A groundbreaking study conducted by the International Agency for the Prevention of Blindness (IAPB) and Kevin Frick, PhD, from Johns Hopkins University reveals that prioritizing better eye health could inject a staggering $50.4 billion annually into the US economy.

Comments for the draft should be submitted by December 13, 2023.

The meeting, being held from October 11-14 in New York City, will feature 4 presentations from ophthalmologists of the New York Eye and Ear Infirmary of Mount Sinai.

Visual acuity changes and conversion to neovascular AMD determined over 3 years in large patient cohort.

According to Roche, faricimab (Vabysmo)showed robust and sustained retinal drying up to 72 weeks and a safety profile consistent with previous studies.

New data, insights on clinical trials, and perspective from researchers will be among the information shared at the 56th annual Retina Society congress being held in New York.

Academy’s 2023 program taking place in San Francisco.

Polish researchers found positive bacterial cultures in premature infants correlated with severe retinopathy of prematurity (ROP), suggesting a potential prognostic marker for early ROP development.

World Sight Day on October 12 highlights the vital role of eye care in workplaces. The International Agency for the Prevention of Blindness urges employers to prioritize eye health, aiming to enhance well-being, safety, and productivity.

The authors of a case series say silicone oil droplets from silicone used to lubricate the McKesson syringes is the most likely cause of the droplets presumed to cause the floaters.

According to the company, a change from base line best corrected visual acuity based on an average at week 44, 48 and 52 serves as the primary endpoint.

The 23rd annual EURETINA Congress took place in Amsterdam, the Netherlands. We spoke with Arshad M. Khanani, MD, MA, FASRS, who provided an overview of his presentation, "Emerging therapies for exudative AMD."

G6501 is a suspension of human allogeneic retinal pigmented epithelial (RPE) cells currently in development for the treatment of GA secondary to age-related macular degeneration (AMD).

The company announced preliminary US net revenues of about $74 million for the injection, approved by the FDA earlier this year.

This milestone was announced by Clearside Biomedical, Inc., Arctic Vision's partner. ARCATUS, also known as XIPERE®, utilizes a revolutionary suprachoroidal delivery platform, offering new hope to patients in China suffering from this vision-threatening condition.

The Person of Vision Award gala will be held on March 14, 2024.

Few injections lowers treatment burden and maintains safety profile.

The new range of pure and premixed gases are intended for medium-term use in retinal surgery.